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Peroxisome proliferator-activated receptors (PPARs), which are known to regulate lipid homeostasis, are tightly controlled by
nutrientavailability,andtheycontrolnutrienthandling.Inthispaper,wefocusonhownutrientscontroltheexpressionandaction
of PPARs and how cellular signaling events regulate the action of PPARs in metabolically active tissues (e.g., liver, skeletal muscle,
heart, and white adipose tissue). We address the structure and function of the PPARs, and their interaction with other nuclear
receptors, including PPAR cross-talk. We further discuss the roles played by diﬀerent kinase pathways, including the extracellular
signal-regulated kinases/mitogen-activated protein kinase (ERK MAPK), AMP-activated protein kinase (AMPK), Akt/protein
kinase B (Akt/PKB), and the NAD+-regulated protein deacetylase SIRT1, serving to control the activity of the PPARs themselves as
well as that of a key nutrient-related PPAR coactivator, PPARγ coactivator-1α (PGC-1α). We also highlight how currently applied
nutrigenomicstrategieswillincreaseourunderstandingonhownutrientsregulatemetabolichomeostasisthroughPPARsignaling.
1.Introduction
1.1. PPARs: Nuclear Receptors Functioning as Metabolic
Sensors. Energyhomeostasisismostlyachievedbyhormonal
and nutrient-mediated control of the expression of genes
encoding metabolic enzymes. Nuclear receptors are respon-
sible for the transcriptional regulation of the vast majority of
the aforementioned genes. These receptors are transcription
factors that respond to small lipophilic hormones, vitamins,
and metabolites. Among the nuclear receptors, the glucocor-
ticoid, thyroid hormone, and estrogen receptors (GR, TR,
and ER, resp.) are important regulators of genes involved
in metabolic fuel homeostasis both during development and
in response to metabolic stress, as well as in the regulation
of cellular energy metabolism. Estrogen-related receptors
(ERRs) also play critical roles in the regulation of cellular
energy metabolism. Other nuclear receptors include the
peroxisome proliferator-activated receptors (PPARs), liver X
receptors (LXRs), the farnesoid X receptor (FXR), retinoid
X receptor (RXR), and hepatocyte nuclear factor-4α (HNF-
4α), all of which are activated by molecules of metabolic
pathways, such as lipids and fatty acids (FAs), and thereby
function as metabolic sensors. The PPARs take part in
the genetic regulation of the complex pathways involved
in mammalian metabolism, including fatty acid oxidation
and lipogenesis that occur in response to nutritional and
physiological stimuli. Taken together, PPARα or NR1C,
PPARδ (also known as PPARβ) or NR1C2, and PPARγ or
NR1C3 constitute group C in subfamily 1 of the superfamily
of nuclear receptors [1].
1.2.PPARs:StructuralFeaturesandInteractionwithCofactors.
Although the PPARs share high degrees of functional and
structural similarities, they are encoded by distinct single-
copy genes located on diﬀerent chromosomes. Human
PPARα is located on chromosome 22 [2, 3], PPARδ on
chromosome 6 [4], and PPARγ on chromosome 3 [5].2 PPAR Research
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Figure1:ModulationoftheactionsofPPARthroughphosphorylationbyERKMAPKorAMPKorthroughregulationofPGC-1αactivityby
various signaling events. Phosphorylation of the PPAR receptors can either increase or decrease their activity. SIRT1-mediated deacetylation
activates PGC-1α,while acetylation by GCN5 inhibits PGC-1α-directed gene expression. Phosphorylation by AMPK or p38 MAPK increases
the stabilization of PGC-1α, whereas Akt/PKB-mediated phosphorylation facilitates its degradation. PRMT1 activates PGC-1α through
methylation at several arginine residues. Activation of PGC-1α that is recruited to ligand-bound PPAR, the latter being complexed with RXR
and/or other nuclear receptors, allows the recruitment of coactivators that acetylate the chromatin, allowing the DNA encoding a particular
PPAR target gene to be transcribed. Ac, acetyl group; ERK MAPK, extracellular signal-regulated kinases/mitogen-activated protein kinase;
AMPK, AMP-dependent protein kinase; Akt/PKB, Akt/protein kinase B; p38 MAPK, p38 mitogen-activated protein kinase; FA, fatty acid
or metabolite from nutrients binding to and activating PPAR; Me, methyl group; P, phosphate group; PGC-1α, peroxisome proliferator-
activated receptor γ coactivator-1α; PPAR, peroxisome proliferator-activated receptor; PPRE, PPAR response element; PRMT1, protein
arginine methyltransferase 1; RXR, retinoid X receptor; NR, nuclear receptor; SIRT1, sirtuin 2 ortholog 1; +, activation; −, inhibition.
The canonical PPAR response element (PPRE) is a DR1
motif (a direct repeat of the sequence separated by a single
nucleotide, preferentially, and adenine [6]) formed by a
5 -a n d3  -AGGTCA half-site [7]. This motif typically is
present in the promoters of PPAR target genes, including
those involved not only in nutrient handling but also in
inﬂammation, cell growth, and diﬀerentiation [8, 9]. The
formation of complexes between PPARs and other factors is
required for the full transcriptional induction of PPAR tar-
gets in a variety of tissues. PPARs are predominantly located
within the nucleus, where they generally heterodimerize
with RXR. In order to achieve their nuclear activity, the
PPARs, like all nuclear receptors, have distinct functional
domains: an N-terminal domain involved in transcriptional
activation, a DNA-binding domain consisting of two zinc-
ﬁnger motifs, the second ﬁnger being involved in binding
to the 5 -DR1 half-site as well as dimerization with RXR
[6], a hinge region which allows for adequate rotation of the
C-terminal domain for interaction with other proteins, and
a C-terminal ligand-binding domain including the ligand-
dependent activation function- (AF-2), important for RXR
heterodimerization and interaction with cofactors [10, 11].
Again, like all nuclear receptors, PPARs act not alone but
in association with cofactors that remodel the structure of
chromatin in order to either permit or prevent transcription.
In the absence of ligand (fatty acids or their derivatives),
PPARs form complexes with corepressors such as NCoR,
RIP140, or SMRT, which repress transcription through the
recruitment of histone deacetylases [12–14]. In the presence
of ligand, on the other hand, coactivators, such as p300,
CBP, or SRC-1 (all being coactivators related to PPAR
function but not primarily associated to nutrient regulation,
indicated as coactivators in Figure 1), become bound to
the amino terminal of PPARγ coactivator-1 (PGC-1, a key
nutrient-modulated coactivator of the PPARs, discussed in
Section 3), then acetylate and remodel chromatin, thus
enhancing gene transcription via the relief of chromatin
condensation (see Figure 1)[ 15–17]. Depending on the cell
type, the ligand-induced conformational changes, and the
sequence of the DNA-binding element, a speciﬁc complex
is formed between the receptor and the coactivators or
corepressors, thus allowing ﬁne-tuning of the physiological
response. This also explains the variety of changes in gene
expression that occur when a nuclear receptor is activated by
diﬀerent ligands.
1.3. Interaction between PPARs and Other Nuclear Receptors.
PPARs can associate with other nuclear receptors, and these
interactions can involve noncanonical PPREs. Although
PPARs and TRs generally compete for interaction with RXR
and thus inhibit their respective activity [18], synergismPPAR Research 3
between PPAR and TR can also occur; an example of this
is given in the context of nutrient handling, involving the
regulationoftheexpressionofthegeneencodinguncoupling
protein 3, playing a role in the handling of fatty acids
within the mitochondria [19]. This interplay has been shown
in rat skeletal muscle [20]a sw e l la si nc o t r a n s f e c t i o n
experiments in rat L6 myoblasts containing a reporter
construct driven by the rat UCP3 promoter [20]. Activation
of UCP3 gene transcription in vivo by thyroid hormone (T3)
requires the presence of fatty acids (the natural ligands of
PPARs; see Section 3), while in the absence of fatty acids,
transcription can be restored by the PPARδ agonist L165041
[20]. The UCP3 gene promoter has been shown to contain
a noncanonical thyroid hormone response element (TRE)
termed TRE1 that is conserved from rodents to humans
[20, 21], and this response element is also recognized by
PPARs [21].
1.4.PPARs:DiﬀerentGenes,DiﬀerentRoles? Itwaspreviously
assumed that the three known isoforms, PPARα,δ,a n d
γ—which display tissue-speciﬁc expression (see Table 1)
and possess diﬀerent gene-regulatory proﬁles—had clearly
distinct roles. For instance, PPARγ, expressed predominantly
in adipose tissue and the immune system, existing as two
distinct proteins γ1a n dγ2, which arise by diﬀerential
transcription start sites and alternative splicing [5], was
assigned the key role as regulator of adipose development,
lipid mobilization, and adipose insulin sensitivity [22],
whereas PPARα-regulated genes were considered to be
associated with lipid oxidation in muscle and liver [23]. The
PPARα target genes include carnitine palmitoyltransferase I
(CPT I), which is involved in the transport of long-chain
fatty acyl groups into the mitochondria, medium-chain acyl-
CoA dehydrogenase (involved in β-oxidation), and (specif-
ically in liver) mitochondrial 3-hydroxy-3-methylglutaryl-
CoA synthase (the rate-limiting enzyme of ketogenesis),
as well as peroxisomal acyl-CoA oxidase (peroxisomal β-
oxidation) and microsomal cytochrome P450 (CYP) FA
hydroxylases. Thus, PPARα w o u l db ee x p e c t e dt op l a y
a critical role in the maintenance of lipid homeostasis
(oxidation and production). Although it seems clear that
it is primarily involved in lipid metabolism, PPARα may
also provide a link between dyslipidemia and diabetes.
Exposure of insulin-sensitive tissues (in particular liver and
skeletal muscle) to excess nonesteriﬁed FA and circulating
triglycerides (triacylglycerol, TAG) induces insulin resistance
[24], and this can be corrected by the administration of
PPARα activators, the actions of which promote the removal
of intracellular lipid through FA oxidation [25]. The PPARδ
isoformispredominantlyexpressedinskeletalmuscle(where
it induces fatty acid oxidation and the expression of largely
the same genes as does PPARα), but it is also expressed in
brain, heart, liver, adipose tissue, and small intestine [26].
This receptor subtype, which is still under active study, is
perhaps the most versatile of the three subtypes, to judge
from its wide tissue distribution. PPARδ has been allocated
a central role in the direction of fuel usage between diﬀerent
organs (for review, see [27]).
1.5. PPAR Cross-Talk and Fine-Tuning of Nutrient Handling.
Because of the overlap in expression proﬁles between the
PPARs [26, 28] (see Table 1), it is perhaps not surprising
that there exists cross-talk among PPARs. Indeed, it has been
shown that nonliganded PPARδ represses the transcriptional
activity of PPARα and PPARγ [29, 30]. Contrasting evidence
exists on a nongenomic action of PPARδ on regulation of
PPARγ signaling. Using transient transfection studies, it has
been shown that the ligand-binding domain of PPARδ, with-
out binding to DNA, exerts ligand-dependent dominant-
negative activity on PPARγ1 signaling [30], although in a
previous study a non-DNA-binding PPARδ derivative failed
t oe x e r ts u c ha ne ﬀect [29]. Since the PPARs act as RXR
heterodimers, it is conceivable that, in analogy to ligand-
dependent RXR competition between PPAR and liver X
receptor (LXR) [31, 32], PPARδ and LXRα [33], PPARα and
TR [34], as well as PPARγ and TR [35], competition for RXR
could occur between the PPAR isoforms. Indeed, the nonge-
nomic dominant-negative eﬀect of PPARδ on PPARγ is
likely to involve RXR sequestration, thus preventing PPARγ-
RXR heterodimerization [30]. Interaction between PPARs
and other nuclear receptors and PPAR cross-talk together
allow for ﬁne-tuning of interorgan nutrient handling, in
concert with the eﬀects of the various signaling molecules
that are common to the nuclear receptors and that direct
their actions.
2. Nutritional Control of Expressionand
ActivationofPPARs
2.1. Nutrients: Natural PPAR Ligands. P P A R sh a v eb e e n
shown to be under nutritional control. Dietary nutrients
and their derivatives (or adipose-derived fatty acids during
food deprivation) directly control PPAR activity since they
are the natural ligands of PPARs. PPARs display the greatest
preference for monounsaturated and polyunsaturated fatty
acids (MUFAs and PUFAs, resp.), as demonstrated by
means of various ligand-binding assays [36, 37]. The fact
t h a te a c hP P A Ra c t i v a t e sad i ﬀerent gene program, despite
their overlapping expressions, would seem to suggest that
PPARs display ligand speciﬁcity. Indeed, the structure of
the ligand-binding pocket diﬀers considerably among the
variousPPARs,asrevealedbyX-raycrystal-structureanalysis
[37, 38]. Despite this, natural fatty acids can be ligands of
all three PPAR isoforms. Using comparative nutrigenomics
analysis, it has been recently shown that, in response to
high-fat diet, the diet-induced target genes of PPARα are
conserved between yeast, mouse, rat, and man, underlining
the importance of nutritional control of PPAR function [39].
Ad i ﬀerent nutrigenomic approach consisted of the use of
synthetic triglycerides composed of one single fatty acid in
combination with gene expression proﬁling to examine the
eﬀects of various individual dietary fatty acids on hepatic
gene expression in mice. Results revealed that (i) increased
fatty acid chain length and degree of unsaturation increased
the number of genes being upregulated and that (ii) genes
regulated by dietary unsaturated fatty acids remained unal-
tered in PPARα knockout mice, identifying PPARα as their4 PPAR Research
Table 1: Tissue distributions of the various PPARs (RNA and protein) in adult rodents and humans. Abbreviations: GI, gastrointestinal;
WAT, white adipose tissue; BAT, brown adipose tissue; CNS, central nervous system. Symbols: −,a b s e n t ;±, barely detectable; +, weak; ++,
moderate; +++, high; ++++, very high (Taken from [26, 28, 45]).
Tissue Protein/mRNA PPARα PPARβ/δ PPARγ
GI tract
Mouse Protein ++++
Human mRNA + or ++ + to ++++ ++ to ++++
Mouse mRNA + or +++
Rat mRNA ++ to ++++ ++ to ++++ + to ++
Liver
Mouse Protein +++
Rat Protein ++++
Human mRNA + to ++++ + or ++ + to ++
Mouse mRNA ++++
Rat mRNA ++++ ++ −
Kidney
Mouse Protein +++
Human mRNA ++ to ++++ + to +++ + to +++
Mouse mRNA +++
Rat mRNA +++ to ++++ +++ ±
Heart
Mouse Protein ++
Human mRNA +++ to ++++ + or +++ ++ to +++
Mouse mRNA ++
Rat mRNA + or +++ + ±
WAT
Human mRNA + ++ ++++
Rat mRNA + ++ +++
BAT
Mouse mRNA +++
Rat mRNA ++++ ++ ++++
CNS
Rat mRNA + + or +++ ±
Brain
Mouse Protein ++
Human mRNA ++ + or +++
Rat mRNA + +++
Skeletal muscle
Mouse Protein +
Human mRNA ++ to ++++ ++ or ++++ + or +++
Mouse mRNA +++ +++ ±
Rat mRNA ++ ++++ ±
Skin
Mouse Protein +++
Rat mRNA + ±
Lung
Mouse Protein ++
Human mRNA + + or +++ ++++
Rat mRNA + ++ +PPAR Research 5
target, and the same genes were upregulated in mice treated
with the PPARα agonist WY14643 [40]. Since the binding of
aligandpromotesaconformationalchangethatispermissive
for interactions with tissue-speciﬁc coactivator proteins (see
Section 3), allowing nucleosome remodeling and activation
of the transcription of cell type-speciﬁc target genes [37, 41],
it is conceivable that upon binding to a ligand-binding
pocket a given fatty acid induces conformational changes,
which diﬀer among the various PPAR subtypes. Given that
the transcriptional activity induced by each PPAR subtype is
cell type speciﬁc [42], the diﬀerent conformations induced
following ligand binding might confer cell speciﬁcity on the
various PPARs (through heterodimerization with diﬀerent
receptors and binding to cell type-speciﬁc cofactors).
2.2. Role of PPARs in the Adaptation to Nutrient Deprivation.
One widely employed way of studying how PPAR expression
and function is controlled by nutrients in diﬀerent tissues
is by imposing nutrient deprivation. The fasting state
inﬂuences the actions of all known PPARs. For instance,
fasting is known to increase PPARα signaling in the liver,
through increased mRNA levels of the coactivator PGC-1α
[43], and thereby tightly to regulate hepatic gluconeogenesis
and FA oxidation. Interestingly, and perhaps paradoxically,
it has recently been shown that during fasting upregulation
of gene expression by PPARδ,n o tP P A R α,i ss e n s i t i v et o
adipose-derived plasma FA, thus assigning a clear role for
PPARδ as a plasma FA sensor in liver [44]. Given the
central role of PPARδ in controlling skeletal muscle lipid
utilization, fasting (which results in a greater reliance on
fatty acids) would be expected to increase PPARδ expression
and/or activity. In line with this, starvation has been
shown to result in a dramatic but transient upregulation
of PPARδ mRNA in rat gastrocnemius muscle [45]. This
correlated with rapid nuclear accumulations of PPARδ and
the coactivator PGC-1α after food deprivation [45]. It has
also been shown that, in skeletal muscle, PPARδ and PGC-
1α physically interact with each other within the nucleus
[46]. This interaction would then lead both to increased
fatty acid levels and to increased expression of genes such
as those for myosin heavy chain I (MHC I), thioesterase
I( M T EI )[ 47], and carnitine palmitoyl transferase 1
(CPT1), as well as uncoupling protein 3 (UCP3) [48, 49],
thereby underlining the role of PPARδ as a key regulator
of muscle-ﬁber switching and fatty acid metabolism. The
transientnatureoftheincreasedPPARexpressionthatoccurs
during starvation (both the mRNA levels and the nuclear
accumulation decreasing once serum FA levels increase [45])
would imply that excessive intracellular fat accumulation
inhibits PPAR expression. Indeed, rat PPARα and PPARδ
mRNA are each shown to be downregulated after a 48-
hour fast [45] and conversely suppression of free fatty acids
(using the antilipolytic drug nicotinic acid) was found to
increase the mRNA levels of skeletal muscle PPARδ [50].
Boththeearlyfastingstateandnicotinicacidtreatmentcause
increased phosphorylation of AMP-activated protein kinase
[45], which is known to interact functionally with, and
stimulate, PPAR (see Section 3). Once serum fatty acid levels
become elevated during food deprivation, the raised muscle
AMPK phosphorylation level falls. Taken together, these data
indicatethattheinitialabsenceofburnablefattyacidsduring
food deprivation triggers a process in which the myocyte is
rapidly “converted” to a cell type dedicated to the uptake
and burning of fat. Once the intracellular FA levels reach a
certain value, the myocyte switches oﬀ AMPK and reduces
PPAR expression throughout the remainder of the starvation
period. Similarly, a downregulation of PPARδ mRNA levels
in human skeletal muscle expression has been reported in
healthy human subjects after a 48-hour fast [51]. Although
data from shorter food-deprivation periods in humans are
lacking, it seems likely that, after food deprivation, there
is a rapid but transient increase in skeletal muscle PPAR
expression in humans too. Activation of the white adipose
tissue PPARγ promotes lipid synthesis and storage [52].
Therefore, during fasting, the action of PPARγ has to be
inhibited. Indeed, in mature adipocytes, during fasting, its
action is inhibited by a physical interaction with the protein
sirtuin 1 (SIRT1) (the mammalian Sir2 ortholog), the result
being lipolysis [53]. In contrast, the action of PPARγ is
enhanced by direct binding to lipin-1, a protein which is
known to promote triacylglycerol storage within adipocytes,
and to be less expressed during fasting, resulting in lipolysis
[54]. There exists cross-talk between PPARγ and PPARδ in
thiscontext:PPARδ inhibits thecontrolofPPARγ expression
[55], enhancing lipolysis.
2.3. Inﬂuence of the Nutritional State on PPAR Action. It
is well known that in the liver PPARα controls fatty acid
oxidation [23], but the role of PPARδ in the liver has
up to now scarcely been assessed. A recent transcriptional
proﬁling analysis using PPARα-v e r s u sP P A R δ-depleted mice
has revealed that PPARδ exerts a distinct role in the liver,
namely in the control of glucose utilization and lipoprotein
metabolism, as well as the suppression of inﬂammation [56],
whereas PPARα mainly controls hepatic lipid homeostasis,
which was especially revealed during fasting, causing drastic
changes in the hepatic gene expression proﬁle of the PPARα-
depleted mice but not in that of the PPARδ-depleted mice
[56]. It should, however, be noted that, as described above,
the same group assigned a predominant role for PPARδ as
FA sensor in liver during fasting, being activated in response
to a rise in plasma FA levels, in contrast to PPARα [44]. It
is conceivable that dietary FAs and adipose-derived FAs may
activate diﬀerent PPAR-related pathways, and more research
is clearly necessary to gain more insight into the respective
roles of PPARα and PPARδ in nutrient handling in liver
and other organs. In Figure 2,a no v e r v i e wo fP P A Ra c t i o n
on nutrient handling in the diﬀerent metabolically active
organs, on the basis of the above data, is depicted.
3.NutrientAvailability-RelatedCytosolic
SignalingPathways DirectlyandIndirectly
ModulatingPPARActivity
3.1. Control of PPAR Phosphorylation by Upstream Signaling
Related to Fuel Use. Activation of cytosolic and nuclear6 PPAR Research
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Figure 2: PPAR action in relation to nutrient handling in metabol-
ically active tissues.
signaling, modulating the activity of PPARs, is nutrient regu-
lated. Recent data have revealed that kinases whose activity is
modulated by the nutritional state can directly act on phos-
phorylationofPPARs.Insulinincreasesphosphorylationand
transcriptionalactivityofPPARα,duetoincreasedactivityof
the extracellular signal-regulated kinases/mitogen-activated
protein kinase (ERK MAPK) pathway [57]. This same
pathway inhibits adipogenesis through phosphorylation and
inactivation of PPARγ [58]. Both actions are in favor of an
increase in insulin sensitivity. Adenosine monophosphate-
activated protein kinase (AMPK) is an energy sensor that
is activated when the cell-energy level is low [59]. Once
activated, AMPK stimulates both glucose uptake and lipid
oxidation to produce energy, while turning oﬀ energy-
consuming processes. Direct proof for phosphorylation of
PPARα by AMPK has not been provided thus far, but it
has been shown that phosphorylation of PPARγ by AMPK
represses both the ligand-dependent and -independent tran-
scriptional activation function of the receptor [60], thus
counteracting adipogenesis and favoring lipid oxidation.
PPARδ phosphorylation and activity are also likely to be
directly controlled by kinase pathways, but to our knowledge
evidence for this has not been obtained yet.
3.2.Nutrient-RelatedControlofPPARActivitythroughActiva-
tion of PGC-1. The aforementioned kinases as well as other
kinases and proteins, functionally associated with nutrient
availability, do not only act directly on the PPARs but also
modulate the activity of important regulators of the activity
of PPARs, namely the PGC-1s, well known as key transcrip-
tional coactivators involved in the control of nutrient and
energy metabolism. Three isoforms of PGC-1 are known
[namely, PGC-1α,P G C - 1 β, and PGC-1-related coactivator
(PRC)]. They each control mitochondrial physiology and
FA oxidation, while exerting an isoform-speciﬁc regulation
of diﬀerent metabolic pathways [61]. PGC-1α and PGC-1β
are highly expressed in heart, skeletal muscle, and brown
adipose tissue, where, via nuclear respiratory factors (NRFs),
they induce expression of genes involved in the regulation
of mitochondrial biogenesis [61]. PGC-1 family members
can interact not only with PPARs but also with other
members of the nuclear receptor superfamily, such as ERR,
LXR, and HNF-4α [62–64], and with distinct transcription
factors and regulatory elements, including cAMP response
element-bindingprotein(CREB),thelipogenictranscription
factor sterol regulatory element-binding protein-1c (SREBP-
1c), and forkhead box O1 (FOXO1) [43, 65–68]. PPARs,
ERR, HNF-4α, and GR commonly bind to LXXLL motifs
present in the N-terminal domain of PGC-1, while other
transcription factors bind to diﬀerent regions of the pro-
tein, hence allowing a coordinated transcriptional response
to nutrient and physiological signals. Although at least
two clinical studies have identiﬁed a correlation between
mutations of the gene encoding PGC-1α and either insulin
resistance or diabetes [69, 70], basic research has produced
contrasting results. For instance, overexpression of PGC-1α,
leading to increased PPARα expression in primary cultures
of rat skeletal muscle cells, induces increased expression of
the mammalian tribbles homolog TRB3, an inhibitor of
Akt signaling [71], a result that implies that PGC-1α has
the potential to cause insulin resistance through PPARα
signaling. Moreover, PGC-1−/− mice are protected against
the insulin resistance induced by a high-fat diet [72].
4.Nutrient-RelatedFactorsControlling
PGC-1Activity
In response to nutrient signaling, (e.g., in the fasting/fed
state, discussed in Section 2), PGC-1 isoforms regulate their
own transcription, but a posttranslational regulation also
occurs. In particular, (i) phosphorylation, (ii) reversible
acetylation, and (iii) methylation are key mechanisms by
which the function of PGC-1α function is maintained.
(i) Three protein kinases directly phosphorylate PGC-
1α. P38 mitogen-activated kinase (P38 MAPK) phospho-
rylates PGC-1α [73], leading to a more active and sta-
ble protein that is unable to bind the p160 corepressor.
Also, AMPK phosphorylates and activates PGC-1 [59]
(Figure 1). Activation of PGC-1α by phosphorylation
through p38 MAPK and AMPK occurs in muscle [74,
75] whereas, in contrast, phosphorylation of PGC-1α in
the liver by Akt/protein kinase B (Akt/PKB, which is a
central kinase in the insulin-signaling cascade) leads to
decreased stability and activity (see [76]; Figure 1). It is
noteworthy that AMPK is constitutively activated in the
muscles of transgenic mice harboring an activated form
of PPARδ [77], while skeletal muscle cells exposed to a
pharmacological PPARδ activator show increased AMPK
activity [78, 79]. (ii) By analogy with the antagonisticPPAR Research 7
phosphorylation induced by AMPK and Akt/PKB, the
protein deacetylase SIRT1 opposes the action of GCN5,
an acetyl transferase. GCN5 inhibits PGC-1 transcriptional
activity by acetylating PGC-1 at several lysine residues [80,
81] while SIRT1 activates PGC-1 by deacetylating it and
induces expression of PGC-1 gene targets (see [82, 83];
Figure 1). SIRT1, located within the cell nucleus, modulates
gene expression in ways that depend on the cellular energy
state, which it senses through the cell’s NAD+ levels. SIRT1
is an important regulator of those metabolic processes that
are initiated by a rise in the intracellular NAD+/NADH
ratio when the energy supply is low. Recently, SIRT1-
mediated deacetylation of PGC-1α was reported to play
a critical role in the regulation of hepatic FA oxidation:
nutrient signaling involving SIRT1 and PGC-1α activated
gluconeogenic and fatty acid oxidation genes in the fasting
liver [82]. Such nutrient signaling gives rise to increases
in pyruvate and NAD+ levels, resulting in increases in the
amount and enzymatic activity of SIRT1. Loss of SIRT1 from
hepatocytes impairs PPARα signaling, resulting in decreased
fatty acid oxidation and leading to the development of
hepatic steatosis on a high-fat diet, whereas overexpression
of SIRT1 induces expression of PPARα gene targets [84].
SIRT1 induces PPARα signaling through deacetylation of
PGC-1α without aﬀecting the formation of the PPARα-
PGC-1α complex: in SIRT-knockdown hepatocytes, PGC-
1α is still recruited to the PPAR response element (PPRE)
of FA oxidation genes [84], but it remains acetylated and
thus unable to induce transcription of PPARα gene targets.
SIRT1 has been identiﬁed as a functional regulator of PGC-
1α that induces a metabolic gene transcription program
of muscle mitochondrial function and fatty acid oxidation
during fasting [82]. Thus, consistent with a switch from
glucose to fatty acid oxidation that occurs in nutrient-
deprivation states, SIRT1 is required for induction and
maintenance of fatty acid oxidation in response to low
glucose concentrations. Importantly, the action of SIRT1
on PGC-1 diﬀers among stimuli, deacetylating PGC-1α
only in response to nutrient signaling, not to glucagon
[82, 85]. In addition, whereas SIRT1 overexpression protects
against both the hepatic steatosis and glucose intolerance
induced by high-fat feeding [86, 87], oligonucleotide knock-
down of hepatic SIRT1 in a rat model of T2DM has
been reported to reduce hyperglycemia by normalizing
basal hepatic glucose production and increasing hepatic
insulin sensitivity, leading to the suggestion that novel
SIRT1 inhibitors targeted at the liver might prove beneﬁcial
in the treatment of T2DM [88]. (iii) Protein arginine
methyltransferase I (PRMT1; Figure 1) coactivates nuclear
receptors [89] and has been reported to induce the PGC-
1α function through methylation at several arginine residues
in the C-terminal region [89]. Further, it has recently
been demonstrated that impaired PRMT1 activity may
be implicated in glucose intolerance in nonobese dia-
betic Goto-Kakizaki rats through disturbed hepatic glucose
metabolism and insulin secretion [90]. An overview of
the above discussed nutrition-related kinases and enzymes
modulating PPAR activity directly or via PGC-1 is given in
Figure 1.
5. Conclusions
The beginning of this century saw a rapid expansion of
research on the obesity-counteracting potential of PPARs. It
is important to consider that dietary changes can drastically
interfere with interorgan signaling, and that PPARs can play
animportantroleinthiscontext.Excessfatsupplyandnutri-
ent deprivation, followed by analysis utilizing comparative
nutrigenomics and transcriptional proﬁling, have rapidly
increased our knowledge on nutrient-mediated regulation of
PPARaction,andhasrevealedthatnutrient-basedregulation
of PPAR action is conserved from yeast to man. PPAR action
is under tight control of upstream signaling through factors
such as SIRT1 and AMPK, having PGC-1 as a target, and
this signaling is also inﬂuenced by the nutritional state.
The further application of potent transcriptomic proﬁling
techniques under diﬀerent dietary conditions will help to
establish which natural ligands might activate each PPAR in
a given cellular context. This research will be important since
it will allow us to assess how even subtle changes in our daily
dietcancausedrasticvariationsinPPAR-mediatedmetabolic
homeostasis. Normalization of lipid and glucose metabolism
may be achieved via pharmacological modulation of PPAR
activitybuttheobtainedresultsarenotalwaysbeneﬁcial(not
discussedinthisreview),whichindicatesthatourknowledge
on the intricate network controlling PPAR action is still
far from complete. The challenge for future research is to
unravel the complex nutrient-inﬂuenced metabolic signaling
involving the aforementioned factors, in order to be able to
“safely” interfere with these processes, as an important step
to relieve the burden of obesity and its related disorders.
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